San Jose, CA, December 1, 2017 – Acepix Biosciences is proud to announce partnership with Yicon (Beijing) Medical Technology Inc. to provide animal model based research and clinical services and products.
Yicon (Beijing) Medical Technology Inc. is one of the leading companies in China that provides services for immuno-oncology, in vivo drug testing, in vivo pharmacology, and translational research, using animal models such as cell line derived xenografts (CDX), patient derived xenografts (PDX), and syngeneic models.
The partnership between Acepix and Yicon will extend these services to the United States market to facilitate and accelerate basic, translational, and clinical research programs. In addition, Acepix and Yicon will co-develop high quality animal tissue based products as research tools and test controls.
About Acepix Biosciences, Inc.
Acepix Biosciences, Inc. is an innovator in developing and providing high quality biological specimens for research and diagnostics. The company also provides high quality, fast turnaround, and economical services in the field of histo-pathology, biomarker discovery, and translational research. Acepix Biosciences is headquartered in San Jose, California. For more information, please visit www.acepixbio.com.